Peter Crowley, Executive Chairman
Peter Crowley joined MTS Health Partners, which makes equity investments in companies within the services sectors of the health care industry, in 2011 as an Operating Partner. Additionally, since April 2008, he has been an operating partner at JH Partners, a private equity firm managing close to $1 billion of institutional funds. Crowley has been involved with JH Partners for more than 14 years as both a director of portfolio companies and an investor. Prior to 2011, Crowley spent 23 years at CIBC World Markets, with the last 14 years as global head of health care investment banking. Transactions include public and private equity, debt financings and mergers and acquisitions transactions for biotechnology, pharmaceutical, specialty pharmaceutical, generics, medical devices, health care services and technology companies.
Crowley sits on the board of several private companies, including Medical Knowledge Group, Ouidad and Gruppo Chiarello. He is also chairman of the public biotech company Progenics Pharmaceuticals. He is also a board member of the Foundation Fighting Blindness, a committee member of the Harvard Alumni Association and a council member of Rockefeller University. Crowley graduated from Harvard College in 1981 and received a MBA from Columbia University in 1985.
Andre Ghetti, Chief Executive Officer
Andre Ghetti, PhD, is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization. Prior to joining AVIVA Biosciences, Dr. Ghetti was involved in drug discovery programs at Aurora Biosciences, and later at Vertex Pharmaceuticals. Dr. Ghetti received his Ph.D. in Molecular and Cellular Physiology from the University of Verona (Italy) and completed his postdoctoral training at the California Institute of Technology. From 1996 to 2001, Dr. Ghetti worked as a staff scientist at the Salk Institute, in La Jolla, California. During the last several years, he has focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate of successful drug discovery and development.
Jack A. Reynolds, Co-Founder and Chairman Emeritus
Jack A. Reynolds, DVM, DACLAM, DACVP and FIATP is a Founding Partner and the Executive Chairman of AnaBios. He recently retired from Pfizer as Senior Vice President of R&D and Worldwide Head of Safety Sciences. With over 30 years in the pharmaceutical industry, he is a seasoned leader within the pharmaceutical industry, having made substantial contributions to numerous development programs and important drug approvals. At Pfizer, he defined and implemented a new paradigm to elucidate, understand, manage and mitigate the inherent risks of medicines. This had a profound impact on Pfizer’s early stage portfolio in reducing attrition, improving drug development effectiveness and expanding their R&D portfolio. This early de-risking of drug development programs is only now being emulated by others.
Dr. Reynolds has the reputation of an industry trailblazer from his extensive work and leadership in building partnerships with regulatory agencies, and through leadership roles in professional societies, industry executive groups and scientific organizations. He is the founder and former Advisory Board Chair of the Drug Safety Executive Council, which now includes a membership of almost 2000 industry professionals and plays an important cross-industry role in collaboratively evaluating, validating and qualifying new technologies for safety testing and decision making. He is board certified in both Veterinary Pathology and Laboratory Animal Medicine and is a Fellow of the International Academy of Toxicological Pathologists. Dr. Reynolds is currently an Adjunct Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the School of Pharmacy, The University of North Carolina at Chapel Hill and is a member of the Scientific Advisory Committee of the Global Alliance for TB Drug Development. In 2004, Dr. Reynolds received a Washington State University Distinguished Alumnus Award for Research and Teaching.
George Goldsmith is Co-Founder and Executive Chairman of COMPASS Pathways, a health care company dedicated to accelerating patient access to evidence-based innovation in mental health and well-being. COMPASS is developing psilocybin therapy through late-stage clinical trials in Europe and the United States for patients with treatment-resistant depression. George’s early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, was a pioneer in collaborative software, and was acquired by Lotus Development. George led the Lotus Institute and created software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership. He eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organization and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organization committed to improving leadership performance and governance effectiveness in regulated sectors. He currently also serves as Tapestry Networks’ non-executive Chairman. He and his wife, Ekaterina Malievskaia, MD, live in London.
Ric Erdman started his business career in 1973 as a consultant with Arthur Andersen in New York City. He has raised more than $20 million in venture capital for companies he has founded and operated. Erdman has been the president of companies that have ranged from $1 million to $100 million in sales, including Digital Automotive Systems, Tylan General, American Gas Compression and OmniPulse Technology. He was a CEO in Residence at Enterprise Partners Venture Capital from 1999 to 2000. He has been a licensed professional engineer in California since 1982. Erdman is active in the San Diego chapters of WPO and YPO.